Vironexis Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|
| VNX-101 | CD19+ leukemias and lymphomas | Phase 1/2 |
| VNX-102 | Multiple Myeloma | IND-Enabling |
| VNX-103 | B-cell Lymphoma | IND-Enabling |
| VNX-201 | Neuroblastoma | Preclinical |
| VNX-202 | Her2+ cancers | Preclinical |
| VNX-203 | Gastric Cancer | Preclinical |
| VNX-204 | Pancreatic Cancer | Preclinical |
| VNX-205 | Prostate Cancer | Preclinical |